Kearns Sayre Syndrome Spectrum Cn381438
A spectrum of mitochondrial disorders related to Kearns-Sayre syndrome, with varying symptoms affecting muscles, eyes, and other organs. Management addresses specific symptoms.
Key facts at a glance
- ICD-10
- G31.82
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
External ophthalmoplegia
(neurologic)Generalized symptoms
(neurologic)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Retinal pigmentary changes
(neurologic)Hearing loss
(neurologic)Endocrine abnormalities
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Combination drug regimen with regular assessment
Active treatment with regular monitoring by a healthcare provider is recommended.
Multisystem surveillance protocol
Comprehensive regular monitoring of cardiac, endocrine, and neurological systems is critical given the spectrum nature of this disorder. Annual assessments should include cardiac evaluation, endocrine testing, and neurological examination.
Endocrine dysfunction management
Treatment of endocrine manifestations including diabetes mellitus, hypoparathyroidism, and growth hormone deficiency with appropriate hormone replacement therapies. Regular endocrine laboratory monitoring guides dosing adjustments.
Additional treatment options
Mitochondrial support therapy
Administration of mitochondrial cofactors including Coenzyme Q10, L-carnitine, and B-complex vitamins to support cellular energy metabolism. Combination approaches may provide synergistic benefits.
medicationEnergy conservation strategies
Implementation of energy conservation and fatigue management techniques helps patients cope with exercise intolerance and muscle weakness. Pacing activities and planned rest periods can improve daily functioning.
lifestylePhysical and occupational therapy
Therapeutic interventions to maintain muscle strength, joint mobility, and functional independence. Occupational therapy addresses activities of daily living adaptations and assistive device needs.
complementaryWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Kearns Sayre Syndrome Spectrum Cn381438?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalMedication Comparisons
Compare medications used to treat Kearns Sayre Syndrome Spectrum Cn381438. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy